SI2542257T1 - Optimizirna monoklonska protitelesa proti inhibitorju poti tkivnega faktorja (TFPI) - Google Patents

Optimizirna monoklonska protitelesa proti inhibitorju poti tkivnega faktorja (TFPI) Download PDF

Info

Publication number
SI2542257T1
SI2542257T1 SI201131308T SI201131308T SI2542257T1 SI 2542257 T1 SI2542257 T1 SI 2542257T1 SI 201131308 T SI201131308 T SI 201131308T SI 201131308 T SI201131308 T SI 201131308T SI 2542257 T1 SI2542257 T1 SI 2542257T1
Authority
SI
Slovenia
Prior art keywords
tfpi
seq
monoclonal antibodies
residues
sequence
Prior art date
Application number
SI201131308T
Other languages
English (en)
Inventor
Peter Scholz
Zhuozhi Wang
Junliang Pan
Joanna Grudzinska
Christian Votsmeier
Jan Tebbe
Jorg Birkenfeld
Nina Wobst
Simone Bruckner
Susanne Steinig
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44542552&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2542257(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of SI2542257T1 publication Critical patent/SI2542257T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Claims (3)

  1. Optimizima monoklonska protitelesa proti inhibitorju poti tkivnega faktorja (TFPI) Patentni zahtevki
    1. Humano monoklonsko protitelo IgG, ki se specifično veže na inhibitor poti tkivnega faktorja, kjer protitelo vsebuje: a) humano težko verigo, ki vsebuje: i. regijo CDR 1 z zaporedjem amino kislin FTFRSYGMD (ki odgovarja ostankom od 27 do 35 zaporedja SEQ ID NO: 1 s substitucijo S35D); ii. regijo CDR 2 z zaporedjem amino kislin SIRGSRSSTYYADSVKG (ki odgovarja ostankom od 50 do 66 zaporedja SEQ ID NO: 1 s substitucijo S55R); iii. regijo CDR 3 z zaporedjem amino kislin LYRYWFDY (ki odgovarja ostankom od 99 do 106 zaporedja SEQ ID NO: 1 s substitucijo K99L); in b) humano lahko verigo, ki vsebuje: i. regijo CDR 1 z zaporedjem amino kislin SGDNLRNYYAH (ki odgovarja ostankom od 23 do 33 zaporedja SEQ ID NO: 2); ii. regijo CDR 2 z zaporedjem amino kislin FYDVNRPS (ki odgovarja ostankom od 48 do 55 zaporedja SEQ ID NO: 2 s substitucijo Y48F inN51V); iii. regijo CDR 3 z zaporedjem amino kislin QSWWDGVPV (ki odgovarja ostankom od 88 do 96 zaporedja SEQ ID NO: 2 s substitucijo D91W).
  2. 2. Humano monoklonsko protitelo IgG po zahtevku 1, kjer a) humana težka veriga vsebuje SEQ ID NO: 7 in b) humana lahka veriga vsebuje SEQ ID NO: 14.
  3. 3. Farmacevtik, ki vsebuje humano monoklonsko protitelo IgG po kateremkoli zahtevku od 1 do 2.
SI201131308T 2010-03-01 2011-03-01 Optimizirna monoklonska protitelesa proti inhibitorju poti tkivnega faktorja (TFPI) SI2542257T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30929010P 2010-03-01 2010-03-01
PCT/US2011/026766 WO2011109452A1 (en) 2010-03-01 2011-03-01 Optimized Monoclonal Antibodies against Tissue Factor Pathway Inhibitor (TFPI)
EP11751244.2A EP2542257B1 (en) 2010-03-01 2011-03-01 Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)

Publications (1)

Publication Number Publication Date
SI2542257T1 true SI2542257T1 (sl) 2018-01-31

Family

ID=44542552

Family Applications (2)

Application Number Title Priority Date Filing Date
SI201131830T SI3345615T1 (sl) 2010-03-01 2011-03-01 Optimizirana monoklonska protitelesa proti zaviralcu poti tkivnega faktorja (TFPI)
SI201131308T SI2542257T1 (sl) 2010-03-01 2011-03-01 Optimizirna monoklonska protitelesa proti inhibitorju poti tkivnega faktorja (TFPI)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SI201131830T SI3345615T1 (sl) 2010-03-01 2011-03-01 Optimizirana monoklonska protitelesa proti zaviralcu poti tkivnega faktorja (TFPI)

Country Status (36)

Country Link
US (3) US9309324B2 (sl)
EP (2) EP2542257B1 (sl)
JP (4) JP6025570B2 (sl)
KR (4) KR101807894B1 (sl)
CN (5) CN107987166A (sl)
AU (1) AU2011223710B2 (sl)
BR (1) BR112012022258A2 (sl)
CA (3) CA2976671C (sl)
CL (2) CL2012002415A1 (sl)
CO (1) CO6620068A2 (sl)
CR (1) CR20120453A (sl)
CU (1) CU23982B1 (sl)
CY (2) CY1119410T1 (sl)
DK (2) DK3345615T3 (sl)
DO (1) DOP2012000239A (sl)
EA (2) EA032189B9 (sl)
EC (2) ECSP12012134A (sl)
ES (2) ES2765418T3 (sl)
GT (1) GT201200252A (sl)
HK (2) HK1232232A1 (sl)
HR (2) HRP20171472T1 (sl)
HU (2) HUE047173T2 (sl)
IL (3) IL221551B (sl)
LT (2) LT2542257T (sl)
ME (2) ME03578B (sl)
MX (2) MX2012010198A (sl)
MY (1) MY174760A (sl)
NZ (2) NZ602115A (sl)
PE (1) PE20160538A1 (sl)
PH (3) PH12018500639A1 (sl)
PL (2) PL3345615T3 (sl)
PT (2) PT2542257T (sl)
RS (2) RS59830B1 (sl)
SG (3) SG183443A1 (sl)
SI (2) SI3345615T1 (sl)
WO (1) WO2011109452A1 (sl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
KR101745394B1 (ko) † 2008-12-22 2017-06-09 노보 노르디스크 에이/에스 조직 인자 경로 억제자에 대한 항체
MY174760A (en) 2010-03-01 2020-05-13 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
JP2013533871A (ja) * 2010-06-30 2013-08-29 ノヴォ ノルディスク アー／エス 組織因子経路インヒビターに特異的に結合することが可能な抗体
SI2694544T1 (sl) * 2011-04-01 2019-06-28 Bayer Healthcare Llc Monoklonska protitelesa proti zaviralcu zunanje poti tkivnega faktorja (TFPI)
RU2014143639A (ru) * 2012-03-30 2016-05-27 Байер Хелскеа Ллк Регулируемые протеазой антитела
US9592297B2 (en) * 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
UY35459A (es) * 2013-03-15 2014-10-31 Bayer Healthcare Llc Anticuerpos profármaco contra el inhibidor de la vía del factor tisular
LT2970497T (lt) * 2013-03-15 2018-03-12 Bayer Healthcare Llc Antikūno prieš tfpi variantai su skirtingu jungimusi ph intervale, skirti farmakokinetikos pagerinimui
JP6660957B2 (ja) * 2015-02-25 2020-03-11 モガム インスティチュート フォー バイオメディカル リサーチＭＯＧＡＭ Ｉｎｓｔｉｔｕｔｅ ｆｏｒ Ｂｉｏｍｅｄｉｃａｌ Ｒｅｓｅａｒｃｈ 新規の抗−ｔｆｐｉ抗体及びこれを含む組成物
JP6664467B2 (ja) 2015-08-19 2020-03-13 ファイザー・インク 組織因子経路インヒビター抗体およびその使用
KR102337683B1 (ko) * 2018-09-21 2021-12-13 주식회사 녹십자 고효율 항-tfpi 항체 조성물
JP7289913B2 (ja) * 2018-10-11 2023-06-12 ファイザー・インク Ｔｆｐｉアンタゴニストのための投薬レジメン
CN112442127A (zh) * 2019-08-29 2021-03-05 苏州康宁杰瑞生物科技有限公司 针对tfpi的单克隆抗体
CN117285632A (zh) * 2022-06-17 2023-12-26 安源医药科技（上海）有限公司 针对tfpi的单克隆抗体及其用途

Family Cites Families (207)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1064396A (en) 1975-02-18 1979-10-16 Myer L. Coval Fractional precipitation of gamma globulin with polyethylene glycol
US4075193A (en) 1976-11-26 1978-02-21 Parke, Davis & Company Process for producing intravenous immune globulin
US4374763A (en) 1979-09-17 1983-02-22 Morishita Pharmaceutical Co., Ltd. Method for producing gamma-globulin for use in intravenous administration and method for producing a pharmaceutical preparation thereof
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4499073A (en) 1981-08-24 1985-02-12 Cutter Laboratories, Inc. Intravenously injectable immune serum globulin
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4597966A (en) 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
US4966852A (en) 1987-07-23 1990-10-30 Monsanto Company DNA clone of human tissue factor inhibitor
ES2044941T5 (es) 1987-08-21 1999-02-16 Mallinckrodt Group Inc Estabilizador de hormonas promotoras del crecimiento.
US4877608A (en) 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
US5096885A (en) 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
WO1989011297A1 (en) 1988-05-27 1989-11-30 Centocor, Inc. Freeze-dried formulation for antibody products
CA2049342A1 (en) 1989-03-27 1990-09-28 Sally Bolmer Formulations for stabilizing of igm antibodies
US6969586B1 (en) 1989-05-16 2005-11-29 Scripps Research Institute Method for tapping the immunological repertoire
US5217954A (en) 1990-04-04 1993-06-08 Scios Nova Inc. Formulations for stabilizing fibroblast growth factor
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
DK261490D0 (da) 1990-10-31 1990-10-31 Novo Nordisk As New pharmaceutical compound
JPH0565233A (ja) 1991-03-08 1993-03-19 Mitsui Toatsu Chem Inc モノクローナル抗体含有凍結乾燥製剤
US6165467A (en) 1991-07-20 2000-12-26 Yoshihide Hagiwara Stabilized human monoclonal antibody preparation
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
EP0539975A1 (en) 1991-10-31 1993-05-05 Teijin Limited Method for immunological assay of free lipoprotein-associated coagulation inhibitor (LACI) and kit therefor
US5849700A (en) 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
DE4223132A1 (de) 1992-07-14 1994-01-20 Deutsche Aerospace Verfahren zur Schrittakt-Regeneration bei der Demodulation von digital modulierten Signalen und Anordnung zum Ausführen des Verfahrens
JPH06153985A (ja) 1992-11-16 1994-06-03 Teijin Ltd モノクローナル抗体
PT686045E (pt) 1993-02-23 2001-04-30 Genentech Inc Estabilizacao por excipientes de polipeptidos tratados com solventes organicos
US5455338A (en) 1993-11-05 1995-10-03 Zymogenetics, Inc. DNA encoding novel human kunitz-type inhibitors and methods relating thereto
DE4344824C1 (de) 1993-12-28 1995-08-31 Immuno Ag Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung
US5580856A (en) 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
JPH0875736A (ja) 1994-09-06 1996-03-22 Chemo Sero Therapeut Res Inst ヒト組織因子凝固系インヒビターの定量法
GB9418092D0 (en) 1994-09-08 1994-10-26 Red Cross Found Cent Lab Blood Organic compounds
US6111079A (en) 1995-06-05 2000-08-29 Bionebraska, Inc. Lead binding polypeptides and nucleotides coding therefore
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
SI1516628T1 (sl) 1995-07-27 2013-10-30 Genentech, Inc. Stabilna izotonična liofilizirana proteinska formulacija
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5902582A (en) 1995-09-05 1999-05-11 Chiron Corporation Use of TFPI inhibitor for treatment of cancer
US6686191B1 (en) 1995-09-22 2004-02-03 Bayer Healthcare Llc Preparation of virally inactivated intravenously injectable immune serum globulin
US7368111B2 (en) 1995-10-06 2008-05-06 Cambridge Antibody Technology Limited Human antibodies specific for TGFβ2
JP3681206B2 (ja) * 1995-12-26 2005-08-10 株式会社三菱化学ヤトロン 抗ファクターＸａ・ティシュファクターパスウェイインヒビター複合体モノクローナル抗体及びその使用
US5770700A (en) 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
AU2150497A (en) 1996-01-25 1997-08-20 Schering Aktiengesellschaft Improved concentrated injection and infusion solutions for intravenous adminis tration
KR100236393B1 (ko) 1996-02-02 1999-12-15 나까니시 히로유끼 사람성장호르몬을 함유하는 의약제제
TW518219B (en) 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
GB9610992D0 (en) 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
US20040052799A1 (en) 1996-11-15 2004-03-18 Astra Aktiebolag Nucleic acid and amino acid sequences relating to Helicobacter pylori for diagnostics and therapeutics
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US6593291B1 (en) 1997-02-06 2003-07-15 Entremed, Inc. Compositions and methods of use of ligands that bind components of the blood coagulation/clotting pathway for the treatment of cancer and angiogenic-based disease
CN1192109C (zh) 1997-03-26 2005-03-09 帝国学院创新有限公司 锚定于细胞膜的抗凝血融合蛋白
US5994511A (en) 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
US6531298B2 (en) 1997-07-21 2003-03-11 The University Of North Carolina At Chapel Hill Factor IX antihemophilic factor with increased clotting activity
US6617156B1 (en) 1997-08-15 2003-09-09 Lynn A. Doucette-Stamm Nucleic acid and amino acid sequences relating to Enterococcus faecalis for diagnostics and therapeutics
DE59806877D1 (de) 1997-08-21 2003-02-13 Siemens Ag Verfahren zum übertragen von nutzdaten, die unterschiedlichen anwendungen zuordenbar sind
US6551795B1 (en) 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
EP1062236A4 (en) 1998-03-12 2005-03-23 Human Genome Sciences Inc 31 HUMAN SECRETED PROTEINS
GB9820525D0 (en) 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
JP2000247903A (ja) 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US20090087878A9 (en) 1999-05-06 2009-04-02 La Rosa Thomas J Nucleic acid molecules associated with plants
US20100293669A2 (en) 1999-05-06 2010-11-18 Jingdong Liu Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
US20040031072A1 (en) 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
BR0014486A (pt) 1999-10-04 2002-09-17 Chiron Corp Composições farmacêuticas contendo polipeptìdeo lìquido estabilizado
US20050208558A1 (en) 1999-10-19 2005-09-22 Applera Corporation Detection kits, such as nucleic acid arrays, for detecting the expression or 10,000 or more Drosophila genes and uses thereof
JP4623825B2 (ja) 1999-12-16 2011-02-02 協和発酵バイオ株式会社 新規ポリヌクレオチド
US20020160934A1 (en) 2000-01-14 2002-10-31 Julie Broadus Nucleic acid sequences from Drosophila melanogaster that encode proteins essential for larval viability and uses thereof
US20030232054A1 (en) 2000-01-25 2003-12-18 Tang Y. Tom Novel nucleic acids and polypeptides
AU2001236005A1 (en) 2000-02-29 2001-09-12 Chugai Seiyaku Kabushiki Kaisha Preparations stabilized over long time
WO2001076621A2 (en) 2000-04-07 2001-10-18 Kline Ellis L Methods and compositions for treating neoplasms
US20110131679A2 (en) 2000-04-19 2011-06-02 Thomas La Rosa Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
US7834146B2 (en) 2000-05-08 2010-11-16 Monsanto Technology Llc Recombinant polypeptides associated with plants
US20040181830A1 (en) 2001-05-07 2004-09-16 Kovalic David K. Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
US7015194B2 (en) 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
US20020082206A1 (en) 2000-05-30 2002-06-27 Leach Martin D. Novel polynucleotides from atherogenic cells and polypeptides encoded thereby
US7138501B2 (en) 2000-06-16 2006-11-21 Human Genome Sciences, Inc. Antibodies that immunospecifically bind BLyS
US20040038878A1 (en) 2000-08-04 2004-02-26 Masahiko Tanikawa Injectable protein formulations
EP1314437B1 (en) 2000-08-11 2014-06-25 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing preparations
US7998929B2 (en) 2000-09-01 2011-08-16 Chugai Seikyaku Kabushiki Kaisha Solution preparations stabilized over long time
CA2423227C (en) 2000-10-12 2011-11-29 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US6912470B2 (en) 2001-05-21 2005-06-28 Ecopia Biosciences, Inc. Genes and proteins involved in the biosynthesis of enediyne ring structures
US7214786B2 (en) 2000-12-14 2007-05-08 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
GB0101879D0 (en) 2001-01-24 2001-03-07 Enzyme Res Lab Ltd Anticoagulants and their uses
EP1379549A2 (fr) 2001-02-07 2004-01-14 Institut Pasteur Sequence du genome de photorhabdus luminescens souche tto1 et utilisations
GB0103424D0 (en) 2001-02-12 2001-03-28 Chiron Spa Gonococcus proteins
US7667004B2 (en) * 2001-04-17 2010-02-23 Abmaxis, Inc. Humanized antibodies against vascular endothelial growth factor
US6891085B2 (en) 2001-04-20 2005-05-10 Pioneer Hi-Bred International, Inc. Nucleic acid encoding the FUS6 antimicrobial polypeptide of Agrotis ipsilon and its use to enhance disease resistance in a plant
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
JP4317010B2 (ja) 2001-07-25 2009-08-19 ピーディーエル バイオファーマ，インコーポレイティド ＩｇＧ抗体の安定な凍結乾燥医薬製剤
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
WO2003033538A1 (fr) * 2001-10-15 2003-04-24 Kirin Beer Kabushiki Kaisha Anticorps anti-hlr-dr
CN1604788B (zh) 2001-10-16 2013-04-17 里克斯金蒂克斯公司 高浓度蛋白制剂及其制备方法
US20040029129A1 (en) 2001-10-25 2004-02-12 Liangsu Wang Identification of essential genes in microorganisms
AU2002363253A1 (en) 2001-11-01 2003-05-12 Gpc Biotech Inc. Endothelial-cell binding peptides for diagnosis and therapy
AU2002363339B2 (en) 2001-11-08 2008-02-07 Abbvie Biotechnology Ltd Stable liquid pharmaceutical formulation of IGG antibodies
CA2473883A1 (en) 2001-11-29 2003-06-12 Wyeth Holdings Corporation Alloiococcus otitidis open reading frames (orfs) encoding polypeptide antigens, immunogenic compositions and uses thereof
US20030138416A1 (en) 2001-12-03 2003-07-24 Jesper Lau Use of glucokinase activator in combination with a glucagon antagonist for treating type 2 diabetes
US20050108791A1 (en) 2001-12-04 2005-05-19 Edgerton Michael D. Transgenic plants with improved phenotypes
US7452539B2 (en) 2001-12-19 2008-11-18 Genentech, Inc. Stabilizing polypeptides which have been exposed to urea
AU2003225535A1 (en) 2002-01-31 2003-09-02 Millennium Pharmaceuticals, Inc. Methods and compositions for treating cancer
CN101721362B (zh) 2002-02-14 2018-07-03 中外制药株式会社 包含抗体的溶液制剂
US7314974B2 (en) 2002-02-21 2008-01-01 Monsanto Technology, Llc Expression of microbial proteins in plants for production of plants with improved properties
US20030180287A1 (en) 2002-02-27 2003-09-25 Immunex Corporation Polypeptide formulation
AU2003222249A1 (en) 2002-03-04 2003-09-22 Fidelity Systems, Inc., Et Al. The complete genome and protein sequence of the hyperthermophile methanopyrus kandleri av19 and monophyly of archael methanogens and methods of use thereof
US7074559B2 (en) 2002-03-06 2006-07-11 Refents of the University of Minnesota Mycobacterial diagnostics
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US20040022792A1 (en) 2002-06-17 2004-02-05 Ralph Klinke Method of stabilizing proteins at low pH
WO2004001007A2 (en) 2002-06-21 2003-12-31 Idec Pharmaceuticals Corporation Buffered formulations for concentrating antibodies and methods of use thereof
EP1539235A2 (en) 2002-07-01 2005-06-15 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
JP2006502116A (ja) 2002-07-12 2006-01-19 メダレックス， インク． タンパク質の酸化分解を防ぐ方法及び組成物
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
DE10239073A1 (de) 2002-08-26 2004-03-11 Basf Ag Verfahren zur fermentativen Herstellung schwefelhaltiger Feinchemikalien
NZ539101A (en) 2002-10-08 2008-08-29 Rinat Neuroscience Corp Methods for treating post-surgical pain by administering a nerve growth factor antagonist and compositions containing the same
KR100542401B1 (ko) 2002-10-23 2006-01-11 한국전자통신연구원 인터넷 차별 서비스 망에서의 연결 수락 제어방법
WO2004050850A2 (en) 2002-12-02 2004-06-17 Abgenix, Inc. Antibodies directed to phospholipase a2 and uses thereof
AU2003293543A1 (en) 2002-12-13 2004-07-09 Abgenix, Inc. System and method for stabilizing antibodies with histidine
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
WO2004058184A2 (en) 2002-12-24 2004-07-15 Rinat Neuroscience Corp. Anti-ngf antibodies and methods using same
EP1601332A4 (en) 2003-03-07 2012-05-02 Verenium Corp HYDROLASES, NUCLEIC ACIDS ENCODING THEM, AND METHODS OF MAKING AND USING SAME
US20050158303A1 (en) 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
KR101208291B1 (ko) 2003-04-04 2012-12-05 노파르티스 아게 고농도 항체 및 단백질 제형
CN1930187B (zh) * 2003-06-27 2015-08-19 艾默根佛蒙特有限公司 针对表皮生长因子受体的缺失突变体的抗体及其使用
RS20100555A (en) 2003-07-15 2011-08-31 Amgen Inc. HUMAN ANTI-NGF NEUTRAL ANTIBODIES AS SELECTIVE NGF SIGNAL ROUTE INHIBITORS
JP5105874B2 (ja) 2003-07-18 2012-12-26 アムジエン・インコーポレーテツド 肝細胞増殖因子に対する特異的結合因子
US7871610B2 (en) 2003-08-12 2011-01-18 Dyax Corp. Antibodies to Tie1 ectodomain
US20060107345A1 (en) 2003-09-30 2006-05-18 Nickolai Alexandrov Sequence-determined DNA fragments and corresponding polypeptides encoded thereby
EP1698640B2 (en) 2003-10-01 2019-06-19 Kyowa Hakko Kirin Co., Ltd. Method of stabilizing antibody and stabilized solution-type antibody preparation
CA2445743A1 (en) 2003-10-08 2005-04-08 The University Of British Columbia Methods for modulating neuronal responses
EP1532983A1 (en) 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
WO2005055930A2 (en) 2003-12-03 2005-06-23 University Of Rochester Recombinant factor viii having increased specific activity
EP1712240B1 (en) 2003-12-25 2015-09-09 Kyowa Hakko Kirin Co., Ltd. Stable water-based medicinal preparation containing antibody
EP3018140A3 (en) 2004-01-09 2016-08-17 Basf Se Inactivation of glutamylpolypeptide synthesis in bacillus
US20060041961A1 (en) 2004-03-25 2006-02-23 Abad Mark S Genes and uses for pant improvement
NZ580607A (en) 2004-05-27 2011-05-27 Crucell Holland Bv Binding molecules capable of neutralizing rabies virus and uses thereof
CA2564791A1 (en) 2004-06-14 2005-12-29 Medimmune Vaccines, Inc. High pressure spray-dry of bioactive materials
US20080008719A1 (en) 2004-07-10 2008-01-10 Bowdish Katherine S Methods and compositions for the treatment of prostate cancer
JP2008505645A (ja) 2004-07-10 2008-02-28 アレクシオン ファーマシューティカルズ， インコーポレイテッド ガン細胞に特異的な抗体を見出すための方法およびそれによって見出される抗体
US20060075522A1 (en) 2004-07-31 2006-04-06 Jaclyn Cleveland Genes and uses for plant improvement
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US20080148432A1 (en) 2005-12-21 2008-06-19 Mark Scott Abad Transgenic plants with enhanced agronomic traits
RU2394839C2 (ru) 2004-12-21 2010-07-20 Астразенека Аб Антитела против ангиопоэтина-2 и их применение
US7566772B2 (en) 2005-01-26 2009-07-28 Amgen Fremont Inc. Antibodies against interleukin-1β
JP5173437B2 (ja) 2005-01-27 2013-04-03 ノビミューン エスアー ヒト抗インターフェロンγ抗体およびその使用の方法
KR20070107079A (ko) 2005-01-28 2007-11-06 와이어쓰 안정화된 액체 폴리펩타이드 제형
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
BRPI0607639B1 (pt) 2005-02-08 2022-04-05 Genzyme Corporation Moléculas de anticorpo humano ou fragmento de ligação a antígeno das mesmas que se ligam e neutralizam tgf-beta1, 2 e 3, uso das mesmas e composição farmacêutica
US8088976B2 (en) 2005-02-24 2012-01-03 Monsanto Technology Llc Methods for genetic control of plant pest infestation and compositions thereof
CA2598792A1 (en) 2005-03-02 2006-09-08 Metanomics Gmbh Process for the production of fine chemicals
DE602006021290D1 (de) 2005-03-04 2011-05-26 Univ Illinois Modulator von coagulationskaskaden und fibrinolytischen kaskaden
CA2600836A1 (en) 2005-03-08 2006-09-14 Pharmacia & Upjohn Company Llc Composition comprising an antibody against macrophage colony-stimulating factor (m-csf) and a chelating agent
EP1858928A2 (en) 2005-03-08 2007-11-28 Pharmacia & Upjohn Company LLC Anti-m-csf antibody compositions having reduced levels of endotoxin
ES2407468T3 (es) 2005-04-18 2013-06-12 Yeda Research And Development Company Limited Formulaciones de anticuerpos anti-hepatitis B (HBV) estabilizadas
US7889636B2 (en) 2005-05-24 2011-02-15 Cisco Technology, Inc. System and method for implementing a mid-call policy in a RSVP environment
GB2426887B (en) 2005-06-04 2009-01-07 Ibm Client responsibilities in messaging systems
WO2007003936A1 (en) 2005-07-02 2007-01-11 Arecor Limited Stable aqueous systems comprising proteins
NZ599176A (en) 2005-08-03 2014-04-30 Immunogen Inc Immunoconjugate formulations
CA2915270C (en) 2005-08-05 2017-07-11 Amgen Inc. Stable aqueous protein or antibody pharmaceutical formulations and their preparation
US20070086433A1 (en) 2005-10-19 2007-04-19 Cunetto Philip C Methods and apparatus for allocating shared communication resources to outdial communication services
JP5138601B2 (ja) 2005-11-21 2013-02-06 サノフィ パストゥール リミテッド 組換えウイルス安定化製剤
US8957187B2 (en) 2005-12-02 2015-02-17 Genentech, Inc. Binding polypeptides and uses thereof
US7669228B2 (en) 2005-12-27 2010-02-23 Cisco Technology, Inc. System and method for changing network behavior based on presence information
WO2007074880A1 (ja) 2005-12-28 2007-07-05 Chugai Seiyaku Kabushiki Kaisha 抗体含有安定化製剤
JP2009525986A (ja) 2006-02-03 2009-07-16 メディミューン，エルエルシー タンパク質製剤
DE102006005094A1 (de) 2006-02-04 2007-08-09 Degussa Gmbh Titandioxid und Polycarboxylatether enthaltende Dispersion
US20070224627A1 (en) 2006-03-23 2007-09-27 Lawrence Horowitz Facilitation of translocation of molecules through the gastrointestinal tract
WO2007147019A2 (en) 2006-06-13 2007-12-21 Zymogenetics, Inc. Il-17 and il-23 antagonists and methods of using the same
KR20090021298A (ko) 2006-06-14 2009-03-02 임클론 시스템즈 인코포레이티드 항-ｅｇｆｒ 항체의 동결건조 제제
PT2426150T (pt) 2006-06-30 2018-01-22 Novo Nordisk As Anticorpos anti-nkg2a e utilizações dos mesmos
US8355333B2 (en) 2006-08-31 2013-01-15 Ciena Corporation Methods and systems for session initiation protocol control of network equipment
US7744890B2 (en) 2006-10-12 2010-06-29 Wyeth Llc Methods and compositions with reduced opalescence
CN101553504A (zh) 2006-12-11 2009-10-07 豪夫迈·罗氏有限公司 Aβ抗体胃肠外制剂
KR101540823B1 (ko) 2007-03-30 2015-07-30 메디뮨 엘엘씨 항체 제제
GB0707938D0 (en) 2007-04-25 2007-05-30 Univ Strathclyde Precipitation stabilising compositions
NZ582436A (en) 2007-06-14 2012-06-29 Biogen Idec Inc Pharmaceutical composition comprising a vla-4 binding antibody, a phosphate buffer and a surfactant
UA107557C2 (xx) 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
PL3002298T3 (pl) * 2007-11-21 2020-03-31 Oregon Health & Science University Przeciwciała monoklonalne anty-czynnik XI i sposoby ich zastosowania
US9308257B2 (en) 2007-11-28 2016-04-12 Medimmune, Llc Protein formulation
CA3102679A1 (en) 2007-12-14 2009-06-25 Birgitte Urso Antibodies against human nkg2d and uses thereof
EP2234600B1 (en) 2007-12-21 2014-08-20 F. Hoffmann-La Roche AG Antibody formulation
WO2009083225A2 (en) 2007-12-28 2009-07-09 Biolnvent International Ab Formulation
RU2010138612A (ru) 2008-02-20 2012-03-27 Джи2 ИНФЛЕММЕЙШН ПТИ ЛТД (AU) ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА ПРОТИВ C5аR
WO2009120684A1 (en) 2008-03-25 2009-10-01 Medimmune, Llc Antibody formulation
JP2011526591A (ja) 2008-06-30 2011-10-13 ノボ・ノルデイスク・エー／エス 抗ヒトインターロイキン−２０抗体
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
HUE036126T2 (hu) 2008-09-19 2018-06-28 Pfizer Stabil folyékony ellenanyag kiszerelés
NZ606283A (en) 2008-11-28 2014-08-29 Abbvie Inc Stable antibody compositions and methods for stabilizing same
EP2196476A1 (en) 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
KR101977846B1 (ko) 2008-12-19 2019-05-14 박스알타 인코퍼레이티드 Tfpi 억제제 및 사용 방법
KR101745394B1 (ko) 2008-12-22 2017-06-09 노보 노르디스크 에이/에스 조직 인자 경로 억제자에 대한 항체
US8618263B2 (en) 2008-12-22 2013-12-31 Novo Nordisk A/S Antibodies against tissue factor pathway inhibitor (TFPI)
EP2403874A1 (en) 2009-03-06 2012-01-11 Genentech, Inc. Antibody formulation
AU2010263058A1 (en) 2009-06-18 2012-01-12 Wyeth Llc Lyophilized formulations for small modular immunopharmaceuticals
PT2473528E (pt) 2009-09-03 2015-03-04 Ablynx Nv Formulações estáveis de polipéptidos e seus usos
EP2332995A1 (en) 2009-12-10 2011-06-15 Bayer Schering Pharma Aktiengesellschaft Neutralizing prolactin receptor antibodies and their therapeutic use
EP3708190A1 (en) 2010-02-26 2020-09-16 Novo Nordisk A/S Stable antibody containing compositions
MY174760A (en) * 2010-03-01 2020-05-13 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
DK2547355T3 (en) 2010-03-19 2017-03-20 Baxalta GmbH TFPI INHIBITORS AND METHODS OF USE
CN105055306B (zh) 2010-05-28 2019-10-01 诺沃—诺迪斯克有限公司 包含抗体和防腐剂的稳定的多剂量组合物
JP6002691B2 (ja) 2011-02-11 2016-10-05 バクスアルタ ゲーエムベーハー 組織因子経路阻害剤に対するアプタマーおよび出血障害治療薬としてのそれらの使用
SI2694544T1 (sl) 2011-04-01 2019-06-28 Bayer Healthcare Llc Monoklonska protitelesa proti zaviralcu zunanje poti tkivnega faktorja (TFPI)
AU2013235567A1 (en) 2012-03-22 2014-10-09 Baxalta GmbH Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
LT2970497T (lt) 2013-03-15 2018-03-12 Bayer Healthcare Llc Antikūno prieš tfpi variantai su skirtingu jungimusi ph intervale, skirti farmakokinetikos pagerinimui
JP6660957B2 (ja) 2015-02-25 2020-03-11 モガム インスティチュート フォー バイオメディカル リサーチＭＯＧＡＭ Ｉｎｓｔｉｔｕｔｅ ｆｏｒ Ｂｉｏｍｅｄｉｃａｌ Ｒｅｓｅａｒｃｈ 新規の抗−ｔｆｐｉ抗体及びこれを含む組成物
JP6664467B2 (ja) 2015-08-19 2020-03-13 ファイザー・インク 組織因子経路インヒビター抗体およびその使用

Also Published As

Publication number Publication date
CU20120126A7 (es) 2013-01-30
CA2976671C (en) 2021-01-12
EP2542257A1 (en) 2013-01-09
CU23982B1 (es) 2014-03-26
US8481030B2 (en) 2013-07-09
HK1232232A1 (zh) 2018-01-05
NZ702494A (en) 2016-09-30
PL2542257T3 (pl) 2018-01-31
USRE47150E1 (en) 2018-12-04
SI3345615T1 (sl) 2020-03-31
RS56409B1 (sr) 2018-01-31
EA032189B9 (ru) 2019-09-30
HRP20171472T1 (hr) 2017-12-01
PT2542257T (pt) 2017-10-09
NZ602115A (en) 2014-12-24
JP2019089807A (ja) 2019-06-13
CN105001335B (zh) 2019-10-25
AU2011223710A1 (en) 2012-09-20
DK3345615T3 (da) 2020-01-20
CA3101298A1 (en) 2011-09-09
CN106188301A (zh) 2016-12-07
ECSP12012134A (es) 2012-09-28
CN102939098A (zh) 2013-02-20
CN107987166A (zh) 2018-05-04
JP2013520996A (ja) 2013-06-10
PT3345615T (pt) 2020-01-17
SG10201502587SA (en) 2015-06-29
EA201892184A1 (ru) 2019-03-29
PH12018500639A1 (en) 2019-07-29
CN110835373A (zh) 2020-02-25
ECSP19025350A (es) 2019-04-30
SG183443A1 (en) 2012-09-27
DOP2012000239A (es) 2013-08-15
JP2020115868A (ja) 2020-08-06
IL221551B (en) 2019-08-29
GT201200252A (es) 2014-04-03
MX2012010198A (es) 2012-10-03
JP6684369B2 (ja) 2020-04-22
CA2791685A1 (en) 2011-09-09
HK1254947A1 (zh) 2019-08-02
CN105001335A (zh) 2015-10-28
LT3345615T (lt) 2020-02-10
AU2011223710B2 (en) 2016-04-14
CA2976671A1 (en) 2011-09-09
KR20130004586A (ko) 2013-01-11
CL2017003218A1 (es) 2018-06-08
US20120108796A1 (en) 2012-05-03
JP6025570B2 (ja) 2016-11-16
ME02894B (me) 2018-04-20
MX354743B (es) 2018-03-16
KR20180091116A (ko) 2018-08-14
CN102939098B (zh) 2016-08-03
KR101974980B1 (ko) 2019-05-07
RS59830B1 (sr) 2020-02-28
HUE047173T2 (hu) 2020-04-28
KR101903931B1 (ko) 2018-10-02
WO2011109452A1 (en) 2011-09-09
KR20190047135A (ko) 2019-05-07
ES2642512T3 (es) 2017-11-16
LT2542257T (lt) 2017-11-27
PH12018500641A1 (en) 2019-07-29
KR101807894B1 (ko) 2017-12-12
PL3345615T3 (pl) 2020-07-13
DK2542257T3 (en) 2017-10-16
PH12018500640A1 (en) 2019-07-29
IL262444A (en) 2018-12-31
HUE036655T2 (hu) 2018-07-30
US20120329996A1 (en) 2012-12-27
JP6475679B2 (ja) 2019-02-27
EP2542257B1 (en) 2017-07-05
CY1119410T1 (el) 2018-03-07
CY1122476T1 (el) 2021-01-27
SG10201903166PA (en) 2019-05-30
US9309324B2 (en) 2016-04-12
CA2791685C (en) 2019-07-23
ES2765418T3 (es) 2020-06-09
CR20120453A (es) 2013-02-27
CO6620068A2 (es) 2013-02-15
EP3345615B1 (en) 2019-10-16
ME03578B (me) 2020-07-20
EP2542257A4 (en) 2013-11-13
EP3345615A1 (en) 2018-07-11
IL277391A (en) 2020-11-30
PE20160538A1 (es) 2016-05-19
JP2017035100A (ja) 2017-02-16
KR20170137218A (ko) 2017-12-12
IL262444B (en) 2021-01-31
HRP20192295T1 (hr) 2020-03-20
CL2012002415A1 (es) 2013-08-23
BR112012022258A2 (pt) 2016-10-25
EA201290849A1 (ru) 2013-05-30
EA032189B1 (ru) 2019-04-30
MY174760A (en) 2020-05-13

Similar Documents

Publication Publication Date Title
SI2542257T1 (sl) Optimizirna monoklonska protitelesa proti inhibitorju poti tkivnega faktorja (TFPI)
RU2012129735A (ru) Антитела к her3 и их применения
EA201491571A1 (ru) МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С АСИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ
AR124676A2 (es) Formulación farmacéutica que comprende una droga biofarmacéutica
CL2008002668A1 (es) Anticuerpo que se une especificamente al polipeptido de linfopoyetina estromal timica (tslp); composicion farmaceutica que lo comprende; acido nucleico, vector de expresion, celula que lo comprende; hibridoma; metodo de produccion del anticuerpo; uso para tratar desorden inflamatorio relacionado a tslp o condicion fibrotica relacionada a tslp.
UA116194C2 (uk) Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном
AR093803A1 (es) Composiciones y metodos de anticuerpos de marcaje de epo
BRPI0606368A2 (pt) anticorpos contra receptor alfa1 de il-13, usos dos mesmos, composição farmacêitica, e método para fabricação da mesma, célula hospedeira recombinante, ácido nucléico, vetor de expressão, método para a produção de um polipeptìdeo , bem como linhagem celular de hibridoma
AR072897A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5
JP2011173914A5 (sl)
CY1121538T1 (el) Μονοκλωνικα αντισωματα εναντι του αναστολεα του μονοπατιου ιστικου παραγοντα (tfpi)
AR072039A1 (es) Anticuerpos contra el virus de la hepatitis c
EA031209B9 (ru) Фармацевтический состав антитела для лечения воспалительного заболевания и способы его применения
EA201101593A1 (ru) КОМПОЗИЦИИ И СПОСОБЫ, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ НАПРАВЛЕННОГО ВОЗДЕЙСТВИЯ АНТИТЕЛ НА БЕЛОК С3b СИСТЕМЫ КОМПЛЕМЕНТА
RU2015150149A (ru) Составы на основе биспецифических антител к il-4/il-13
AR068566A1 (es) Proteinas fijadoras de antigeno de factor de crecimiento del tipo factor de crecimiento epidermico fijador de heparina
UA102867C2 (uk) Антитіла до cxcr4 та їх застосування у лікуванні раку
UA107211C2 (uk) Стабілізовані склади, які містять антитіла до рецептора інтерлейкіну 6 (il-6r)
MX2009006891A (es) Anticuerpos cd44.
RU2009148886A (ru) Рсв-специфичные связывающие молекулы и средства для их получения
MY162564A (en) Modified binding proteins inhibiting the vegf-a receptor interaction
AR085955A1 (es) Proteinas de union al antigeno
EA201070730A1 (ru) Гуманизированные антитела, специфичные к фактору фон виллебранда
SI2970497T1 (sl) Variante protitelesa anti-TFPI z diferencialno vezavo preko območja pH za izboljšane farmakokinetične lastnosti
SI2718320T1 (sl) Molekule, ki vežejo anti-Pseudomonas psl in njihova uporaba